25 August 2023: Clinical Research
Exploring the Impact of Positional Sleep Apnea in a Turkish Population: Unveiling the Untold Story
Makbule Ozlem Akbay ABCDEF* , Canan Gunduz Gurkan ABCDEF , Ayse Ezgi Ak BCDEF , Sema Sarac ABCDEFDOI: 10.12659/MSM.941425
Med Sci Monit 2023; 29:e941425
Table 4 Polysomnography findings in OSA patients with vs without e-POSA.
| OSA patients | p value | |||
|---|---|---|---|---|
| Without e-POSA (n=578) | With e-POSA (n=204) | |||
| Median (min–max) | Median (min–max) | |||
| 7 (0–24) | 6 (0–21) | 0.197 | ||
| Total | 395.0 (205.0–519.5) | 406.8 (246.0–508.0) | ||
| Supine | 184.50 (33.50–423.00 | 218.00 (32.00–426.50) | ||
| Lateral | 203.75 (33.00–469.50) | 191.50 (40.00–420.00) | ||
| Total | 40.4 (6.3–123.8) | 12.9 (5.0–65.0) | ||
| Supine | 56.6 (.0–132.0) | 23.0 (2.4–100.1) | ||
| Non-supine | 23.1 (4.3–121.6) | 1.7 (0.10–4.9) | ||
| REM | 39.0 (0.0–120.0) | 7.6 (0.0–81.0) | ||
| Non-REM | 39.8 (0.0–123.8) | 12.7 (2.5–67.0) | ||
| 84.9 (45.0–99.5) | 87.3 (48.0–98.5) | |||
| 10.5 (.0–115.5) | 10.2 (1.0–71.1) | 0.699 | ||
| 43.5 (.0–225.0 | 37.0 (1.0–214.0) | 0.189 | ||
| Stage 1 | 3.8 (.0–18.9) | 3.2 (.2–17.9) | 0.054 | |
| Stage 2 | 67.0 (1.5–90.3) | 62.8 (7.8–88.6) | ||
| Stage 3 | 17.9 (.0–47.9) | 21.2 (2.0–48.3) | ||
| Stage REM | 9.4 (.0–28.7) | 9.9 (.0–28.6) | 0.472 | |
| 70.0 (41.0–160.0) | 68.0 (48.0–150.0) | |||
| 72.0 (30.0–91.0) | 82.0 (32.0–92.0) | |||
| 94.0 (73.0–99.0) | 95.0 (85.0–98.0) | |||
| 16.9 (0.1–100.0) | 3.3 (0.0–100.0) | |||
| 42.6 (0.26–127.6) | 13.7 (3.5–197.0) | |||
| 20.7 (1.6–54.5) | 20.5 (14.2–36.9) | 0.458 | ||
| OSA – obstructive sleep apnea; e-POSA – exclusive positional OSA; ESS – Epworth Sleepiness Scale; TST – total sleep time; AHI – apnea-hypopnea index; REM – rapid eye movement; SaO2 – oxygen saturation; SIT90% (%TST) – the percentage of time spent at oxygen saturation below 90% in TST; ODI – oxygen desaturation index; MAD – mean apnea-hypopnea duration. | ||||